| 000 | 01905 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517093935.0 | ||
| 264 | 0 | _c20170913 | |
| 008 | 201709s 0 0 eng d | ||
| 022 | _a1558-8238 | ||
| 024 | 7 |
_a10.1172/JCI85183 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLock, Rebecca | |
| 245 | 0 | 0 |
_aCotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. _h[electronic resource] |
| 260 |
_bThe Journal of clinical investigation _c06 2016 |
||
| 300 |
_a2181-90 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAnilides _xadministration & dosage |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aGenes, Neurofibromatosis 1 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMAP Kinase Kinase Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMechanistic Target of Rapamycin Complex 1 |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aMultiprotein Complexes _xmetabolism |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aNerve Sheath Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aNeurofibromin 1 _xgenetics |
| 650 | 0 | 4 |
_aNucleocytoplasmic Transport Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aProtein Serine-Threonine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 | _aSignal Transduction |
| 650 | 0 | 4 |
_aTOR Serine-Threonine Kinases _xmetabolism |
| 700 | 1 | _aIngraham, Rachel | |
| 700 | 1 | _aMaertens, Ophélia | |
| 700 | 1 | _aMiller, Abigail L | |
| 700 | 1 | _aWeledji, Nelly | |
| 700 | 1 | _aLegius, Eric | |
| 700 | 1 | _aKonicek, Bruce M | |
| 700 | 1 | _aYan, Sau-Chi B | |
| 700 | 1 | _aGraff, Jeremy R | |
| 700 | 1 | _aCichowski, Karen | |
| 773 | 0 |
_tThe Journal of clinical investigation _gvol. 126 _gno. 6 _gp. 2181-90 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1172/JCI85183 _zAvailable from publisher's website |
| 999 |
_c26001311 _d26001311 |
||